FDA ANDA · ANDA206697
EXENATIDE
Sponsor: AMNEAL
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA206697
TYPE
ANDA
ORIGINAL APPROVAL
2024-11-19
LATEST ACTION
2026-10-02
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
EXENATIDE SYNTHETICDiscontinued
EXENATIDE SYNTHETIC 300MCG/1.2ML (250MCG/ML) · INJECTABLE · SUBCUTANEOUS
EXENATIDE SYNTHETICDiscontinued
EXENATIDE SYNTHETIC 600MCG/2.4ML (250MCG/ML) · INJECTABLE · SUBCUTANEOUS
Approval history
2026-10-02Labeling · Supplement 6 · standardAP
2026-10-02Labeling · Supplement 9 · standardAP
2026-10-02Labeling · Supplement 7 · standardAP
2024-11-19UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →